Synonyms: CDP-323 | CDP323
Compound class:
Synthetic organic
Comment: Zaurategrast (CDP-323) is a small molecule inhibitor of α4-containing integrin complexes that was developed by Celltech [3]. It was intended as a new oral drug treatment for multiple sclerosis [2]. Zaurategrast has the same mechanism of action as the approved MS therapeutic natalizumab. Zaurategrast is an ester prodrug whose active entity is CT7758 [1].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
(2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoic acid |
International Nonproprietary Names ![]() |
|
INN number | INN |
9166 | zaurategrast |
Synonyms ![]() |
CDP-323 | CDP323 |
Database Links ![]() |
|
CAS Registry No. | 455264-31-0 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL4303708 |
GtoPdb PubChem SID | 440816856 |
PubChem CID | 10186367 |
Search Google for chemical match using the InChIKey | KYHVWHYLKOHLKA-FQEVSTJZSA-N |
Search Google for chemicals with the same backbone | KYHVWHYLKOHLKA |
Search PubMed clinical trials | zaurategrast |
Search PubMed titles | zaurategrast |
Search PubMed titles/abstracts | zaurategrast |
UniChem Compound Search for chemical match using the InChIKey | KYHVWHYLKOHLKA-FQEVSTJZSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | KYHVWHYLKOHLKA-FQEVSTJZSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Zaurategrast (links to external site)
Cat. No. HY-70073 |